BillionToOne, Inc. is a precision diagnostics company that develops molecular diagnostics for prenatal screening and liquid biopsy using a single molecule next-generation sequencing (smNGS) platform. The company's technology, powered by patented Quantitative Counting Templates (QCTs), enables the detection and quantification of genetic targets at the single-molecule level from cell-free DNA (cfDNA). Its product portfolio includes UNITY, a non-invasive prenatal test (NIPT) for assessing fetal risk of recessive conditions and aneuploidy, and the Northstar suite of pan-cancer liquid biopsy tests, which include Northstar Select for therapy selection, Northstar Response for treatment monitoring, and Northstar Origin for identifying tissue of origin. BillionToOne serves healthcare providers and patients in the prenatal and oncology markets, offering tests that provide insights from a single blood draw. The company was founded by Oguzhan Atay and David Tsao and launched its first commercial product, UNITY, in 2019.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage billiontoone.com
Sector Healthcare IR page investors.billiontoone.com/news-releases/news-release-details/billiontoone-reports-second-quarter-2026-results-and-reiterates
Tags
prenatal screening, liquid biopsy, molecular diagnostics, cell-free dna, oncology, non-invasive prenatal testing, single molecule sequencing, genetic testing, UNITY, Unity Complete, Unity Confirm, Northstar Select, Northstar Response, Northstar Origin, Quantitative Counting Templates, QCTs
Press page billiontoone.com/news-media

Metrics

Valuation  
Market cap $ 5.921B
Market cap (USD) $ 5.921B
P/E 787.16
PEG —
P/BV 10.45
P/S 19.41
P/OCF 240.76
P/FCF 376.83
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.6%
ROI 1.4%
ROIC 2.9%
Profit margin 2.4%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity 15.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 45
Quality score -16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Revenue 305.112M 0 0
Net profit 7.454M — —
Free cash flow 15.714M — —

Figure FY 2025 FY 2024 FY 2023
Share price 81.84 — —
P/FCF 238.56 — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 24.7M 41.6M
↳ YoY growth +68.4%
Borrowings, current (USD) — — 0.00 0.00
Borrowings, non-current (USD) — — 51.5M 57.2M
Lease liabilities (USD) — — 57.9M 51.7M
Cash and deposits (USD) 54.7M 97.3M 191M 496M
Right-of-use assets (USD) — — 51.7M 46.7M
Net debt (borrowings + leases - cash) (USD) — — -82.1M -387M
Cash flow detail
Operating cash flow (USD) — -53.7M -41.4M 24.6M
Purchases of property, plant and equipment (USD) — -6.17M -5.4M -8.88M
Purchases of intangible assets (USD) — 0.00 0.00 -41,000
Change in receivables (cash effect) (USD) — -2.59M -15.6M -16.9M
Change in inventories (cash effect) (USD) — -1.41M -1.54M -8.81M
Change in payables (cash effect) (USD) — 151,000 877,000 1.78M
Share buybacks (cash effect) (USD) — 0.00 -546,000 0.00
Interest paid (cash effect) (USD) — -2.58M -3.92M -4.65M
Income taxes paid (cash effect) (USD) — 0.00 -9,000 -487,000
Share-based compensation (USD) — 4.85M 8.36M 15.9M
Operating cash flow before change in receivables (USD) — -51.1M -25.8M 41.5M
Free cash flow (OCF - PPE - intangibles) (USD) — -59.8M -46.8M 15.7M
Income detail
Research and development expense (USD) — 22.4M 36.6M 49.4M
Total comprehensive income (USD) — -82.7M -41.6M 5.66M
Comprehensive income to owners (USD) — -82.7M -41.6M 5.66M
Reported Mar 11, 2026 Mar 11, 2026 Mar 11, 2026 Mar 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.

Financial Highlights:

●Total revenue of $123.0 million in the third quarter of 2026, compared to $83.5 million in the third quarter of 2025, an increase of 47%.

●Prenatal clinical testing revenue was $104.3 million in the third quarter of 2026, an increase of 41% from the third quarter of 2025.

●Oncology clinical testing revenue was $17.1 million in the third quarter of 2026, 96% higher than the $8.7 million reported in the third quarter of 2025.

●Gross profit margin was 71% in the third quarter of 2026, compared to 70% in the third quarter of 2025, a one percentage-point increase year-over-year.

●206,000 tests delivered in the third quarter of 2026, compared to 165,000 tests delivered in the third quarter of 2025, an increase of 25%.

Skip to Main Content BillionToOne LogoBillionToOne Logo

Products

Oncology Prenatal

Technology

Our Technology Publications EMR Integrations

Careers

Working with us Open Positions

Company

Mission, Vision, Values Leadership & Board Company Milestones

News & Media

Press Releases Events Media Coverage Social Media

Investors

Contact

Press Releases

October 14, 2026

2026

2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

Share this post

Copy URL

https://www.billiontoone.com/news-media/billiontoone-to-report-third-quarter-2026-financial-results-on-november-4-2026
LinkedIn X

News & Media

Press Releases

October 14, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

Read Article
Press Releases

October 14, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

Read Article

Press Releases

October 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Read Article
Press Releases

October 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Read Article

Press Releases

September 2, 2026

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

Read Article
Press Releases

September 2, 2026

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

Read Article

Press Releases

September 1, 2026

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

Read Article
Press Releases

September 1, 2026

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

Read Article

Press Releases

August 18, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Read Article
Press Releases

August 18, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Read Article

Press Releases

August 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Read Article
Press Releases

August 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Read Article

Press Releases

July 20, 2026

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Read Article
Press Releases

July 20, 2026

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Read Article

Press Releases

July 15, 2026

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

Read Article
Press Releases

July 15, 2026

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

Read Article

Press Releases

June 29, 2026

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

Read Article
Press Releases

June 29, 2026

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

Read Article

Press Releases

May 27, 2026

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

Read Article
Press Releases

May 27, 2026

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

Read Article

Press Releases

May 6, 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

Read Article
Press Releases

May 6, 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

Read Article

Press Releases

May 1, 2026

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

Read Article
Press Releases

May 1, 2026

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

Read Article

BillionToOne Logo

We are ONE team, working
toward ONE goal — to detect
disease ONE molecule at a time.

CAP Accredited - College of American Pathologists Logo

LinkedIn X formerly Twitter

What We Offer

Our Technology Publications Products

Explore

News & Media Press Releases Media Coverage Events

About Us

Careers Patient Portal IT Security Compliance

Skip to Main Content BillionToOne LogoBillionToOne Logo

Products

Oncology Prenatal

Technology

Our Technology Publications EMR Integrations

Careers

Working with us Open Positions

Company

Mission, Vision, Values Leadership & Board Company Milestones

News & Media

Press Releases Events Media Coverage Social Media

Investors

Contact

Press Releases

October 7, 2026

2026

2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

MENLO PARK, Calif., OCT. 7, 2026 -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response®, a tissue-free, methylation-based liquid biopsy assay utilizing patented single-molecule counting technology to measure the absolute number of circulating tumor DNA (ctDNA) molecules, with a commercially available tumor-informed ctDNA assay for advanced cancer patients undergoing treatment. The study found that Northstar Response tracked disease dynamics on par with or better than the tumor-informed comparator, without requiring tissue sequencing.

The retrospective real-world study, published in The Journal of Liquid Biopsy, evaluated 169 paired samples from 61 patients, with 71 samples from 36 patients that had sequential concurrent draws for the two assays collected within seven days of each other. Quantitative results, after patient-specific baseline normalization, across repeated measurements were shown to be closely aligned (conditional R² = 0.97). Across evaluable sequential pairs, the two approaches reached the same conclusion of the change in tumor burden direction in 94% of cases (67 of 71). 

Importantly, in all of the divergent cases, Northstar Response results were concordant with the ground truth substantiated by imaging and/or biopsy, indicating that the tumor-informed results were either false-positives or false-negatives. For instance, Northstar Response detected progression in cases where the tumor had evolved since the original biopsy, including a case of hormone receptor conversion in advanced breast cancer. Together, the cases illustrate the particular value of tumor-agnostic monitoring to track tumor burden and evolution.

"The ability to combine cancer-associated methylation with single-molecule precision to track changing tumor signal directly from blood is game-changing, as so many patients in the clinic will benefit," said Vaia Florou, MD, MS, Associate Professor Division of Oncology at the Huntsman Cancer Institute at the University of Utah. "These results showing that a standardized assay can deliver precise longitudinal monitoring without tissue dependency are incredibly relevant for those of us practicing on the frontlines of cancer care."

Since Northstar Response is not limited to alterations selected from an earlier tissue sample at a fixed point in time, it can capture clinically meaningful changes in disease biology that emerge under treatment pressure. Northstar Response’s simplified workflow can also significantly accelerate the start of molecular monitoring of treatment, potentially by weeks, and enable testing when tissue is unavailable, inadequate, or difficult to biopsy. 

“Not only does Northstar Response deliver highly accurate insight into how disease is evolving during treatment, but it also has the added advantage of a streamlined and efficient workflow that can bring molecular testing to more patients,” said Allen Chen, MD, Vice President of Oncology Clinical Development and Medical Affairs at BillionToOne. “Treatment monitoring must be both reliable and practical for it to be effective in routine oncology care. These results show that clinicians do not need to compromise one for the other.” 

About Northstar Response

Northstar Response is BillionToOne's tissue-free, methylation-based ctDNA assay purpose-built for treatment response monitoring in patients with cancer. Powered by the company's patented QCT™ molecular counting platform -- the only multiplex technology capable of counting DNA molecules at the single-molecule level -- Northstar Response quantifies tumor burden through serial blood draws with no dependence on tumor tissue at any stage of the patient journey.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's proprietary single-molecule next-generation sequencing (smNGS) platform is the only multiplex technology that can detect and precisely quantify genetic targets at the physical limit of detection, down to the single DNA molecule. Enabled by Quantitative Counting Templates™ (QCTs™), the platform quantifies disease-related DNA fragments with single base-pair resolution, providing absolute quantification. For more information, visit www.billiontoone.com .

Disclaimer

Northstar Response may produce false-positive or false-negative results. Test results are not a guarantee of the presence or absence of disease or treatment response and should not be used as the sole basis for medical decision-making. Results should be interpreted in conjunction with the patient's clinical presentation, radiographic findings, and other diagnostic information. Northstar Response is intended to complement, not replace, standard clinical and radiographic assessment of disease status. Northstar Response is a laboratory-developed test (LDT) performed in a CLIA-certified and CAP-accredited laboratory. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical performance of Northstar Response. These statements are based on management’s current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne’s control. These and additional risks and uncertainties could affect BillionToOne’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in BillionToOne’s Annual Report on Form 10K, most recently filed Quarterly Report on Form 10-Q, and other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne’s views as of any date subsequent to the date of this press release.

Reference

Choksi A, Varga MG, Farmer T, et al. Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors. The Journal of Liquid Biopsy. Volume 14, 2026, 100669.

Media Contact

Rachel Ford Hutman
[email protected]

‍

Share this post

Copy URL

https://www.billiontoone.com/news-media/billiontoones-tissue-free-northstar-response-r-demonstrates-on-par-to-superior-cancer-treatment-monitoring-vs-tumor-informed-assay-new-peer-reviewed-study-finds
LinkedIn X

News & Media

Press Releases

October 14, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

Read Article
Press Releases

October 14, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

Read Article

Press Releases

October 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Read Article
Press Releases

October 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Read Article

Press Releases

September 2, 2026

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

Read Article
Press Releases

September 2, 2026

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

Read Article

Press Releases

September 1, 2026

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

Read Article
Press Releases

September 1, 2026

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

Read Article

Press Releases

August 18, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Read Article
Press Releases

August 18, 2026

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Read Article

Press Releases

August 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Read Article
Press Releases

August 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

Read Article

Press Releases

July 20, 2026

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Read Article
Press Releases

July 20, 2026

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Read Article

Press Releases

July 15, 2026

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

Read Article
Press Releases

July 15, 2026

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

Read Article

Press Releases

June 29, 2026

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

Read Article
Press Releases

June 29, 2026

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

Read Article

Press Releases

May 27, 2026

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

Read Article
Press Releases

May 27, 2026

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

Read Article

Press Releases

May 6, 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

Read Article
Press Releases

May 6, 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

Read Article

Press Releases

May 1, 2026

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

Read Article
Press Releases

May 1, 2026

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

Read Article

BillionToOne Logo

We are ONE team, working
toward ONE goal — to detect
disease ONE molecule at a time.

CAP Accredited - College of American Pathologists Logo

LinkedIn X formerly Twitter

What We Offer

Our Technology Publications Products

Explore

News & Media Press Releases Media Coverage Events

About Us

Careers Patient Portal IT Security Compliance

Prompts

BillionToOne, Inc. (ticker BLLN), listed in United States.

ETFs Holding BillionToOne, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 3.86% 53,729 $ 4.872M Aug 31, 2026
SPIT 1.32% 4,932 $ 447.184K Aug 31, 2026
TMSL 0.09% 20,436 $ 2.452M Jun 30, 2026
MSSM 0.01% 893 $ 80.968K Aug 31, 2026